Navigation Links
Renewal of agreement between Ipsen and the Salk Institute supports cutting-edge research

La Jolla----Ipsen and the Salk Institute for Biological Studies announced today that they are renewing the Ipsen Life Sciences Program at the Salk Institute. The mission of the partnership is to advance knowledge in the field of proliferative and degenerative diseases through fundamental and applied biology research.

The Ipsen Life Sciences Program led by the Salk Institute's Inder Verma, Ph.D., Irwin and Joan Jacobs Chair in Exemplary Science will for a period of three years, sponsor four research programs through targeted and innovation grants. Ipsen will provide funding for targeted research programs carried out at the Salk Institute by researchers on novel therapeutic concepts for the treatment of pituitary adenomas, cancer and neurodegenerative diseases. Innovation grants will fund the exploration of advanced scientific concepts. Dr. Verma is one of the world's leading authorities in cancer biology.

Over the last 3 years, the partnership between the Salk Institute and Ipsen has delivered significant scientific advances in the cancer field such as the development of biological models mimicking human cancerous processes as well as identification of specific cells driving tumor growth. In addition, the development of stem cells technology has opened up promising new vistas of research in neurodegenerative diseases.

Marc de Garidel, Chairman and Chief Executive Officer of Ipsen, stated "At a time when the magnitude and scope of the life sciences revolution challenge the imagination, it is critical for a biopharmaceutical company to secure close links with the leading academic institutions worldwide. The collaboration between Ipsen and the Salk Institute perfectly fits in our new strategy of increased focus on our key assets, investment in growth levers and leverage of our footprint. By capitalizing on partnerships with first-class research organizations, Ipsen will strengthen its links with the medical and scientific community so as to develop innovative therapies tailoring the needs and expectations of patients and physicians."

"Continuing our partnership with Ipsen Life Sciences reaffirms our commitment to the highest level of biological research, impacting human life globally," said Salk Institute president William R. Brody.


Contact: Andy Hoang
Salk Institute

Related biology news :

1. Erg gene key to blood stem cell self-renewal
2. UNC awarded $6.2 million renewal grant by NIH Rare Diseases Research Network
3. MU signs $5 million agreement with Coulter Translational Research Partnership Program
4. Epitomics Signs Agreement With Bayer for Antibody Technology
5. PharmaEngine, Inc. and Merrimack Pharmaceuticals, Inc. Enter into a Licensing and Collaboration Agreement on PEP02 (MM-398), Nanoliposomal Irinotecan
6. NextCAT secures license agreement for advanced biofuel technology from Wayne State
7. DSM and Codexis Sign Enzyme Supply Agreement
8. Ben-Gurion U. and PTT Chemical sign R&D agreement to commercialize green algae strain
9. DSM and Codexis Sign Enzyme Supply Agreement
10. Sangart, Inc. Announces Cooperative Research and Development Agreement With the U.S. Navy to Evaluate MP4 Molecule in Traumatic Brain Injury
11. Agilent Technologies Expands Agreement to Offer AMDeC Members Preferential Pricing on Products Through AMDeC F.I.R.S.T.™ Vendor Partnership Program
Post Your Comments:
(Date:4/15/2016)... CHICAGO , April 15, 2016  A ... companies make more accurate underwriting decisions in a ... offering timely, competitively priced and high-value life insurance ... health screenings. With Force Diagnostics, rapid ... and lifestyle data readings (blood pressure, weight, pulse, ...
(Date:3/31/2016)... Florida , March 31, 2016 ... ) ("LegacyXChange" or the "Company") LegacyXChange ... potential users of its soon to be launched online ... ( ) will also provide potential ... use of DNA technology to an industry that is ...
(Date:3/22/2016)... 22, 2016 According ... Market for Consumer Industry by Type (Image, Motion, ... (Communication & IT, Entertainment, Home Appliances, & ... to 2022", published by MarketsandMarkets, the market ... reach USD 26.76 Billion by 2022, at ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
(Date:6/23/2016)... June 23, 2016 ... 2016;12(1):22-8 Published recently ... peer-reviewed journal from touchONCOLOGY, Andrew D Zelenetz ... of cancer care is placing an increasing burden ... expensive biologic therapies. With the patents on many ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the ... Convention Center and will showcase its product’s latest features from June 26 to ... a scientific poster on Disrupting Clinical Trials in The Cloud during the conference. ...
(Date:6/23/2016)... Connecticut (PRWEB) , ... June 23, 2016 , ... ... introduce a new line of intelligent tools designed, tuned and optimized exclusively for ... September 12–17 in Chicago. The result of a collaboration among several companies with ...
Breaking Biology Technology: